Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:16 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 20-F | 20-F |
| Reported | Mar 27, 2026 | Mar 20, 2025 | Mar 14, 2024 | – | – |
| Revenue | $75.4M | $10.1M | – | – | – |
| Cost of revenue | $96.4M | $11.4M | – | – | – |
| Research and development | $117.7M | $138.4M | $130.5M | $142.0M | $134.8M |
| Selling, general and administrative | $131.9M | $101.1M | $46.7M | $31.9M | $31.9M |
| Operating income | -$270.5M | -$241.4M | -$179.7M | -$168.0M | -$165.0M |
| Interest expense | $36.7M | $9.29M | $45.1M | $8.90M | $1.10M |
| Income tax | $1.97M | $1.53M | -$19.5K | -$24.4M | -$23.9M |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M | -$142.1M |
| EPS, basic | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
| EPS, diluted | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
| Weighted shares, basic | 266.1M | 255.2M | 173.9M | 95.0M | 72.1M |
| Weighted shares, diluted | 266.1M | 255.2M | 173.9M | 95.0M | 72.1M |
| Margins and growth | |||||
| Operating margin | -358.9% | -2385.6% | – | – | – |
| Net margin | -381.4% | -2180.5% | – | – | – |
| Revenue growth, year over year | +644.9% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 20-F | 20-F |
| Reported | Mar 27, 2026 | Mar 20, 2025 | Mar 14, 2024 | – | – |
| Cash and equivalents | $104.1M | $227.4M | $239.6M | $382.4M | $310.3M |
| Accounts receivable | $24.0M | $15.0K | $109.0K | $121.0K | – |
| Inventory | $33.2M | $4.14M | – | – | – |
| Total current assets | $435.9M | $660.9M | $275.3M | $425.8M | $347.0M |
| Property, plant and equipment | $63.6M | $49.6M | $34.9M | $35.2M | $33.5M |
| Intangible assets | $19.8M | $12.4M | – | $0 | $65.0K |
| Total assets | $589.1M | $782.7M | $375.4M | $490.3M | $405.6M |
| Accounts payable | $3.08M | $1.97M | $103.0K | $531.0K | $431.0K |
| Total current liabilities | $73.4M | $60.7M | $44.7M | $46.4M | $28.6M |
| Total liabilities | $410.9M | $355.4M | $263.9M | $191.6M | $92.2M |
| Shareholders' equity | $178.1M | $427.3M | $111.5M | $298.7M | $313.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 20-F | 20-F |
| Reported | Mar 27, 2026 | Mar 20, 2025 | Mar 14, 2024 | – | – |
| Operating cash flow | -$283.6M | -$206.3M | -$145.6M | -$112.3M | -$117.9M |
| Capital expenditures | $19.0M | $22.1M | $11.0M | $10.8M | $8.86M |
| Free cash flow | -$302.6M | -$228.3M | -$156.6M | -$123.1M | -$126.7M |
| Depreciation and amortization | $8.30M | $7.55M | $6.57M | $7.42M | $8.46M |
| Stock-based compensation | $14.4M | $15.5M | $11.3M | $12.0M | $9.94M |
| Investing cash flow | $158.5M | -$394.6M | -$11.0M | -$10.8M | -$8.86M |
| Financing cash flow | -$4.34M | $589.6M | -$883.0K | $223.6M | $284.1M |
| Net change in cash | -$123.2M | -$11.5M | -$142.4M | $72.1M | $156.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 19.2% | 152.9% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 9, 2026 | 266.3M | +0.1% | SEC |
| Aug 10, 2026 | 266.2M | 0.0% | SEC |
| May 13, 2026 | 266.2M | 0.0% | SEC |
| Mar 26, 2026 | 266.1M | 0.0% | SEC |
| Nov 11, 2025 | 266.1M | 0.0% | SEC |
| Aug 11, 2025 | 266.1M | 0.0% | SEC |
| May 7, 2025 | 266.1M | 0.0% | SEC |
| Mar 19, 2025 | 266.1M | +0.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.